Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT04681248 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT04681248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Lead sponsor
Leap Therapeutics, Inc.
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, carcinosarcoma, endometrial cancer, esophageal neoplasm, gastric adenocarcinoma, gastric cancer, gastroesophageal cancer, ovarian cancer, squamous cell carcinoma, uterine cancer